In this episode of "A New Healthcare Era", host Dhanvin Yajaman discusses an exciting new therapy for type 2 diabetes - a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) that aims to control blood sugar. Dhanvin delves into the mechanisms behind this therapy, highlighting its potential benefits such as improved blood sugar control, weight loss, and increased patient convenience. However, he also addresses some of the potential drawbacks of the treatment, including cost and the risk of side effects. Looking ahead, Dhanvin explores the potential future implications of the GIP/GLP-1 therapy, including personalized treatment approaches and the development of innovative new treatments for metabolic conditions. Whether you're a healthcare professional or simply interested in the latest advancements in healthcare, this episode is a must-listen.